“Update on SLE Classification, Treatment and Complications” (Hybrid Event)

Michelle Petri, MD, MPH
Professor
Johns Hopkins University School of Medicine

Michelle Petri is a Professor of Medicine in the Division of Rheumatology and Director of the Lupus Center at the Johns Hopkins University School of Medicine and Johns Hopkins Hospital in Baltimore, Maryland. She earned her medical degree from Harvard Medical School in Boston, Massachusetts, and completed her internship and residency in Internal medicine at Massachusetts General Hospital. Thereafter, Professor Petri completed her Postdoctoral Fellowship in Allergy, Immunology, and Rheumatology at the University of California, San Francisco. She subsequently earned her master’s in Public Health and Epidemiology from Johns Hopkins University Bloomberg School of Public Health. Professor Petri’s research focuses on several aspects of systemic lupus erythematosus (SLE), including atherosclerosis, antiphospholipid syndrome (APS), lupus nephritis, and pregnancy. The Hopkins Lupus Cohort, started by Professor Petri in 1987, is a longitudinal study of the incidence and pathogenesis of thrombotic events and coronary artery disease in SLE. She is a Master of the American College of Rheumatology, and was Chair of the Lupus Now Education Program.

____________________________________________________________________________________________

Join Meeting!

OBJECTIVES:

• Analyze classification/diagnosis of SLE: consideration of how little positive ANA helps
• Analyze treatment pitfalls: review of the harm that reliance on prednisone causes over time. Targeted biologics and small molecules offer hope of efficacy without such major toxicity
• Identify Complications of SLE: discuss why SLE remains the 5-6th leading cause of death in young minority women in the U.S

FACULTY DISCLOSURES:

Dr. Petri has indicated the following relevant financial relationships with commercial interests:

Commercial Interest/Organization

Aurina
Exagen
Janssen
Annexon Bio
AstraZeneca
Aurinia
Boxer Capital
Cabaletto Bio
Caribou Biosciences Inc
CTI Clinical Trial and Consulting Services
CVS Health
Escient Pharmaceuticals
Emergent Biosolutions
Gentibio
GSK
Horizon Therapeutics
iCell Gene Therapeutics
Merck EMD Serono
Nexstone Immunology
Proviant
Regeneron Pharmaceuticals
Seismic Therapeutic
Sinomab Biosciences
Takeda
Tenet Medicines Inc
TG Therapeutics
UCB
Zydus

PLANNING COMMITTEE DISCLOSURE:

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.
Dr. Weiss has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                          Commercial Interest/Organization
Consultant/Contractor                                              Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

TARGET AUDIENCE:
Primary care physicians.

ACCREDITATION:
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.